Q-omics provides the consensus-scored SNHG26 profile across patient tissues and cancer cell-line models. SNHG26 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, SNHG26 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, SNHG26 RNA expression shows 17,467 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, HNSC, and THYM as cancer lineages where SNHG26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNHG26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNHG26 survival associations across molecular data types. SNHG26 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNHG26 RNA expression–survival associations across cancer types. High SNHG26 expression shows unfavorable associations in COAD, KIRP, STAD, LIHC and UCEC, but favorable associations in UCS. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for SNHG26 RNA expression.
This table summarizes SNHG26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SNHG26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNHG26 shows lower tumor expression in THCA, BRCA and UCEC and higher tumor expression in HNSC, KIRC and LUSC. The HNSC box plot shows higher SNHG26 RNA expression in tumor versus normal tissue (log2 FC = +1.038, t-test p < 0.001).
This table shows molecular features associated with SNHG26 in patient tissues and cancer cell lines. In patient samples, SNHG26 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
